Abstract:Irisin, a recently identified novel myokine, drives brown-fat-like conversion of white adipose tissues and has been proposed to mediate beneficial effects of exercise on metabolism. Circulating irisin was significantly reduced in type 2 diabetes patients; however, no evidence is available about its association with metabolic syndrome (MetS) and effects of adiposity and muscle mass on circulating irisin have been controversial. Cross-sectional data on socio-demographic, lifestyle, clinical characteristics and serum irisin were collected for 1,115 community-living Chinese adults with central obesity. Associations of serum irisin with MetS (central obesity plus any two of the following four factors (raised blood pressure (BP), raised fasting plasma glucose (FPG), raised triglyceride (TG), and reduced HDL cholesterol) and each component of MetS were analyzed using multivariable logistic regression. Among the 1,115 obese Chinese adults with a mean age of 53.2(±7.2) years, serum irisin levels (log-transformed) were significantly reduced in subjects with MetS and raised FPG than their control groups (p = 0.034 and 0.041, respectively). After adjustment for potential confounders, serum irisin was significantly associated with reduced risks of MetS and raised FPG, with odds ratios (ORs) (95% CI) per standard deviation of log-transformed irisin of 0.796 (0.505-0.959, p = 0.027) and 0.873 (0.764-0.998, p = 0.046), respectively. Associations of irisin with raised BP, raised TG and reduced HDL were not statistically significant ((ORs) (95% CI): 0.733(0.454-1.182, p = 0.202), 0.954(0.838-1.086, p = 0.478) and 1.130(0.980-1.302, p = 0.092), respectively). Stepwise multivariable linear regression analysis showed that fasting insulin, HbA1c and albumin/globulin ratio were negatively associated with serum irisin level with statistical significance (all p-values <0.05) and waist circumference was negatively associated with serum risin with marginally statistical significance (p = 0.055). These results imply that irisin may play an important role in insulin resistance and MetS and should be confirmed in future prospective studies.

Relationship between irisin and metabolic diseases

Irisin Reverses Insulin Resistance in C2C12 Cells Via the P38-Mapk-pgc-1α Pathway.

Irisin is inversely associated with intrahepatic triglyceride contents in obese adults.

The role of irisin in kidney diseases

Irisin a Novel Metabolic Biomarker: Present Knowledge and Future Directions

Association of serum irisin with metabolic syndrome in obese Chinese adults.

Irisin: A Hope in Understanding and Managing Obesity and Metabolic Syndrome

Irisin in atherosclerosis

Irisin and Energy Metabolism and the Role of Irisin on Metabolic Syndrome

Irisin Is Related to Non-Alcoholic Fatty Liver Disease (NAFLD)

Irisin is Regulated by CAR in Liver and is a Mediator of Hepatic Glucose and Lipid Metabolism.

Role of irisin in physiology and pathology

Association of Serum Irisin Levels with Fat Mass Percentage in Adults with Abdominal Obesity

Irisin Levels Are Associated with Urotensin II Levels in Diabetic Patients.

Irisin Stimulates Browning of White Adipocytes Through Mitogen-Activated Protein Kinase p38 MAP Kinase and ERK MAP Kinase Signaling

Elevated Circulating Irisin is Associated with Lower Risk of Insulin Resistance: Association and Path Analyses of Obese Chinese Adults

Potential role of irisin in digestive system diseases

Irisin: Linking Metabolism with Heart Failure.

Hyperirisinemia is independently associated with subclinical hypothyroidism: correlations with cardiometabolic biomarkers and risk factors

Irisin in patients with nonalcoholic fatty liver disease

Irisin, Energy Homeostasis and Male Reproduction